Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those ...
These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...
In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.
MyChesCo on MSN4d
Johnson & Johnson Showcases Promising Data on Nipocalimab for gMG at AAN Annual MeetingHOUSE, PA — Johnson & Johnson presented new data on its investigational treatment, nipocalimab, at the 2025 American Academy ...
This CME program is designed to enhance neurologists' understanding and management of generalized myasthenia gravis (gMG). Participants will explore how comprehensive assessment of disease burden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback